# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
1. Name and Address of Reporting Niihara Yutaka	2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director X 10% Owner					
(Last) (First) 21250 HAWTHORNE BLVI	3. Date of Earlie 02/19/2020	3. Date of Earliest Transaction (Month/Day/Year) 02/19/2020					X Officer (give title below) Other (specify below)  Chairman and CEO					
(Street) TORRANCE, CA 90503		4. If Amendmen	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
(City) (State)	,	Table L. Non-Derivative Securities Acqu						uired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)	itle of Security 2. Transaction 2A. Deemed 3. Execution Date, if Tr		3. 4. Securities Acquired (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)			5. Amount of Securities		6.	7. Natu Indirec Benefic Owners	t cial ship		
			Code	V	Amount	(A) or (D)	Price		(I) (Instr. 4)			
Common stock, \$0.001 par value	02/19/2020		P		8,000	A	\$ 1.7 (1)	10,368,543	3	D (2)		
Common stock, \$0.001 par value	02/20/2020		P		15,500	A	\$ 1.8 (3)	10,384,043	3	D (2)		
Common stock, \$0.001 par value	02/21/2020		P		24,500	A	\$ 1.84 (4)	10,408,543	3	D (2)		
Common stock, \$0.001 par value								92,794		I	By Ho Intern Hospi Inc. (5	ational ce,
Common stock, \$0.001 par value								63,000		I	By So Niiha	
Reminder: Report on a separate line	for each class of sec	urities beneficially	owned dire	ectly	or indirect	tlv						
Tomas August on a separate and	101 64611 64655 61 666			Po	ersons w	ho re in thi	s form	are not requ	ction of infor ired to respo OMB contro	ond unless	SEC 147	74 (9-02)
	Table II	- Derivative Secur										
1. Title of Derivative Security (Instr. 3)  2. Conversion Date (Month/Date Security Security	Execution I y/Year) any	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	5.	6 a: (I	and Expiration Date (Month/Day/Year) U		7. Title and Amount of Juderlying Securities Instr. 3 and	Title and mount of delerlying curities astr. 3 and Security (Instr. 5)  8. Price of Derivative Security Security (Instr. 5)  9. Num Derivative Security Security General Security Security Owned Follow Report Transa (Instr.		Ownership of Indirect Corm of Beneficia Ownersh (Instr. 4) Direct (D) r Indirect		
		Code V	(A) (I	Е	Oate Exercisable		ration 1	Amount or Number of Shares				

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		

Niihara Yutaka 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE, CA 90503	X	X	Chairman and CEO		
--	---	---	------------------	--	--

### **Signatures**

1	Yutaka Niihara, M.D., M.P.H.	02/21/2020
	**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.69 to \$1.72, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4.
- (2) The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
- (3) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.65 to \$1.91, inclusive.
- (4) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.68 to \$1.91, inclusive.
- (5) Hope International Hospice, Inc, is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.